Related Experiment Video
Updated: Jul 15, 2026
09:54
Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
Published on: November 4, 2018
Gene therapy for type I glycogen storage diseases
Janice Y Chou1, Brian C Mansfield
1Section on Cellular Differentiation, Heritable Disorders Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA. chouja@mail.nih.gov
Current Gene Therapy
|April 14, 2007
Summary
Type I glycogen storage diseases (GSD-I) involve deficiencies in the glucose-6-phosphatase-alpha (G6Pase-alpha) system, impacting blood glucose. Gene therapy shows promise for treating GSD-I, particularly with adeno-associated virus (AAV) vectors.
Area of Science:
- Biochemistry
- Genetics
- Pediatric Medicine
Background:
- Type I glycogen storage diseases (GSD-I) result from deficiencies in the glucose-6-phosphatase-alpha (G6Pase-alpha) system, crucial for maintaining blood glucose homeostasis.
- GSD-I encompasses GSD type Ia (G6Pase-alpha deficiency) and GSD type Ib (glucose-6-phosphate transporter deficiency), both causing metabolic disturbances.
- GSD-Ib patients additionally exhibit neutropenia and myeloid dysfunctions, complicating treatment options.
Purpose of the Study:
- To review the current state of gene therapy for Type I glycogen storage diseases.
- To evaluate the efficacy of different gene therapy vectors in animal models of GSD-Ia and GSD-Ib.
- To explore the potential of gene therapy as a long-term treatment strategy for GSD-I.
Main Methods:
- Utilized animal models that accurately mimic human GSD-Ia and GSD-Ib disorders.
- Evaluated adenovirus- and adeno-associated virus (AAV)-mediated gene therapies for GSD-Ia in these models.
- Assessed the metabolic and hematological improvements in GSD-Ib animal models treated with adenoviral constructs.
Main Results:
- Adenovirus-mediated gene therapy provided short-term correction for GSD-Ia, primarily in the liver.
- AAV-mediated gene therapy demonstrated longer-term correction for GSD-Ia, targeting both liver and kidney, with efficacy varying by AAV serotype.
- Adenoviral gene therapy in GSD-Ib models showed improvements in metabolic profile and myeloid function.
Conclusions:
- Gene therapy, particularly using AAV vectors, holds significant potential for long-term treatment of GSD-Ia.
- While gene therapy for GSD-Ib is less advanced, initial results are encouraging for metabolic and myeloid function.
- Further refinements in gene therapy approaches are expected to offer substantial long-term benefits for patients with Type I glycogen storage diseases.
Related Concept Videos
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:20Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...